研究设计与统计

订阅

MedSci主页 / 所有栏目 / 研究设计与统计

Graphpad Prism如何做统计？

2021-08-09 MedSci原创 MedSci原创

Graphpad Prism
关注

Graphpad Prism如何做统计-Graphpad Prism快速作图技巧-问题4.

《梅斯直播课——SCI大神在线：Graphpad Prism快速作图技巧》

回答问题4： Graphpad Prism如何做统计？

 

欢迎点赞、评论、分享

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2069217, encodeId=7541206921e64, content=<a href='/topic/show?id=519b1420696' target=_blank style='color:#2F92EE;'>#PHP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14206, encryptionId=519b1420696, topicName=PHP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed May 18 02:03:08 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063218, encodeId=49eb1063218ba, content=来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a3f5640529, createdName=ms3000000148710543, createdTime=Sat Oct 23 19:39:16 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595467, encodeId=f503159546eff, content=<a href='/topic/show?id=0b7e824178' target=_blank style='color:#2F92EE;'>#Graphpad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8241, encryptionId=0b7e824178, topicName=Graphpad)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 11 08:03:08 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006382, encodeId=697c1006382b0, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210809/002e1c215a3049668f9ea5ad57d6a1a6/9a5498638c6441d9b7d26f8ad04e1445.jpg, createdBy=11b25547896, createdName=千与千寻果子, createdTime=Mon Aug 09 17:15:57 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2022-05-18 jeanqiuqiu

    #PHP#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2069217, encodeId=7541206921e64, content=<a href='/topic/show?id=519b1420696' target=_blank style='color:#2F92EE;'>#PHP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14206, encryptionId=519b1420696, topicName=PHP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed May 18 02:03:08 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063218, encodeId=49eb1063218ba, content=来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a3f5640529, createdName=ms3000000148710543, createdTime=Sat Oct 23 19:39:16 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595467, encodeId=f503159546eff, content=<a href='/topic/show?id=0b7e824178' target=_blank style='color:#2F92EE;'>#Graphpad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8241, encryptionId=0b7e824178, topicName=Graphpad)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 11 08:03:08 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006382, encodeId=697c1006382b0, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210809/002e1c215a3049668f9ea5ad57d6a1a6/9a5498638c6441d9b7d26f8ad04e1445.jpg, createdBy=11b25547896, createdName=千与千寻果子, createdTime=Mon Aug 09 17:15:57 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-10-23 ms3000000148710543

    来了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2069217, encodeId=7541206921e64, content=<a href='/topic/show?id=519b1420696' target=_blank style='color:#2F92EE;'>#PHP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14206, encryptionId=519b1420696, topicName=PHP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed May 18 02:03:08 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063218, encodeId=49eb1063218ba, content=来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a3f5640529, createdName=ms3000000148710543, createdTime=Sat Oct 23 19:39:16 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595467, encodeId=f503159546eff, content=<a href='/topic/show?id=0b7e824178' target=_blank style='color:#2F92EE;'>#Graphpad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8241, encryptionId=0b7e824178, topicName=Graphpad)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 11 08:03:08 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006382, encodeId=697c1006382b0, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210809/002e1c215a3049668f9ea5ad57d6a1a6/9a5498638c6441d9b7d26f8ad04e1445.jpg, createdBy=11b25547896, createdName=千与千寻果子, createdTime=Mon Aug 09 17:15:57 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-08-11 仁医06

    #Graphpad#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2069217, encodeId=7541206921e64, content=<a href='/topic/show?id=519b1420696' target=_blank style='color:#2F92EE;'>#PHP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14206, encryptionId=519b1420696, topicName=PHP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed May 18 02:03:08 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063218, encodeId=49eb1063218ba, content=来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a3f5640529, createdName=ms3000000148710543, createdTime=Sat Oct 23 19:39:16 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595467, encodeId=f503159546eff, content=<a href='/topic/show?id=0b7e824178' target=_blank style='color:#2F92EE;'>#Graphpad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8241, encryptionId=0b7e824178, topicName=Graphpad)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 11 08:03:08 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006382, encodeId=697c1006382b0, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210809/002e1c215a3049668f9ea5ad57d6a1a6/9a5498638c6441d9b7d26f8ad04e1445.jpg, createdBy=11b25547896, createdName=千与千寻果子, createdTime=Mon Aug 09 17:15:57 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-08-09 千与千寻果子

    受益匪浅

    0

相关资讯

Graphpad Prism性别差异怎么作图？

Graphpad Prism性别差异怎么作图-Graphpad Prism快速作图技巧-问题3.

Graphpad Prism和SPSS的分析结果有差异怎么办？

Graphpad Prism和SPSS的分析结果有差异，应该怎么选择-Graphpad Prism快速作图技巧_2